JPRN-UMIN000011671招募中1 期
Phase I/II study eribulin mesylate and lapatinib for metastatic in patients with human epidermal growth factor receptor 2-positive breast cancer previously treated with an anthracycline, taxane and trastuzumab - Phase I/II study eribulin mesylate and lapatinib
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •a)Patients with brain metastases with symptoms b)Patients with the body cavity fluid marked (pleural effusion, ascites, pericardial effusion). However, it can be registered if good control due to the administration of adhesion agent. c)Patients with synchronous double cancer, not including lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy d)Patients with complications is determined causing serious problems in the implementation of treatment - Patients with poor control diabetes - Patients with activity infection - Patients with pulmonary fibrosis or interstitial pneumonia on chest X-ray - Patient with protocol difficult-to-treat caused by the mental state or neuropsychiatric disorders - Patients with watery diarrhea chronic - Patients with ileus, significant bleeding tendency, and gastrointestinal bleeding - Patients with uncontrolled angina and myocardial infarction and heart disease merger severe cases with heart failure that developed within three months e)Pregnant or breast-feeding women, or women of child bearing potential who intend to become pregnant
研究者
相似试验
进行中（未招募）
1 期
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas.Solid Tumors including LymphomasEUCTR2016-001894-34-Outside-EU/EEAEisai Inc.23
已完成
1 期
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor-negativeStage IV Breast CancerTriple-negative Breast CarcinomaNCT02120469City of Hope Medical Center27
已完成
1 期
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung CancerNon Small Cell Lung CancerNCT01126736Eisai Inc.98
终止
2 期
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerHER2-positive Breast CancerMetastatic Breast CancerNCT01912963Dana-Farber Cancer Institute32
进行中（未招募）
1 期
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryMalignant Abdominal NeoplasmMalignant Retroperitoneal NeoplasmMalignant Scrotal NeoplasmMalignant Solid NeoplasmMalignant Spermatic Cord NeoplasmLiposarcomaNCT03361436OHSU Knight Cancer Institute15